| B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders M Tanguay, M Boutin, A Laumaea, M Salaciak, A Mendoza, C Cassis, ... Vaccine 40 (9), 1203-1207, 2022 | 11 | 2022 |
| A single-armed proof-of-concept study of Lymfit: A personalized, virtual exercise intervention to improve health outcomes in lymphoma survivors in the pandemic C Angelillo, WL Tock, M Salaciak, RER Reid, RE Andersen, C Maheu, ... Plos one 19 (1), e0275038, 2024 | 2 | 2024 |
| Pilot Randomized Controlled Trial of Lymfit: A Theory-Guided Exercise Intervention for Young Adults with Lymphoma WL Tock, NA Johnson, RE Andersen, M Salaciak, C Angelillo, ... Healthcare 12 (11), 1101, 2024 | | 2024 |
| STAT6 mutations enriched at diffuse large B-cell lymphoma relapse reshape the tumor microenvironment A Benoit, MJ Abraham, S Li, J Kim, R Estrada-Tejedor, R Bakadlag, ... International Journal of Hematology 119 (3), 275-290, 2024 | | 2024 |
| Interleukin-17A Directly Signals to Bone Marrow-Derived Hematopoietic Stem and Progenitor Cells to Promote Their Expansion and Differentiation in Vitro CG Losada, WWL Poon, M Salaciak, S Amghar, NA Johnson, ... Blood 142 (Supplement 1), 5587-5587, 2023 | | 2023 |
| Revealing the Heterogeneity of T Cells in a Relapsed Hodgkin Lymphoma Patient Treated with Immunotherapy using Single-cell RNA Sequencing M Salaciak McGill University (Canada), 2022 | | 2022 |
